Because Borrelia burgdorferi and B. microti are transmitted by the same tick vector, concurrent infection may occur. There is a relative paucity of information regarding concurrent infection, possibly because of the high rate of subclinical infection with B. microti. The majority of babesial infections are asymptomatic [4, 6, 8] ; in serological studies on Nantucket Island and Block Island, RI, only 6 of 19 and 6 of 34 seropositive subjects, respectively, had medical histories indicating prior babesiosis infection. It is not known whether subclinical babesiosis predisposes individuals to experience more severe episodes of Lyme disease or increases the likelihood of poor outcomes because of inadequate treatment for babesiosis. Some patients with "atypical" Lyme disease (for instance, Lyme disease without erythema migrans) may actually have babesiosis instead.
In 1993 we initiated a population-based study on Nantucket Island to study the long-term outcomes of Lyme disease [9] . This large cohort was also evaluated for acute Lyme disease and concurrent or previous serological evidence of babesiosis. The population-based design permits us to characterize the epidemiology of concurrent infection and the subsequent course of Lyme disease.
Materials and Methods
Participants. From 1993 through 1995, surveys were mailed to all 6046 adult (aged у17 years) permanent residents of Nantucket Island. The island, located off the southeastern coast of Massachusetts, has the highest reported incidence of Lyme disease in the country [10] . Adults were identified by census files. The survey inquired about prior diagnoses of Lyme disease or babe- 27 (8) siosis, Lyme-related symptoms, and tick exposure. Two follow-up mailings were sent to nonrespondents. All respondents who reported a clinician's diagnosis of Lyme disease or a history of a positive Lyme serological test were invited for clinical evaluation. In addition, a random sample of the remaining respondents, balanced by age tertile and gender, were invited as potential controls. An outline of the sampling scheme for this study evaluation has been detailed elsewhere [9] . Informed consent was obtained. The study was approved by the Institutional Review Board of the Brigham and Women's Hospital, Boston.
Clinical evaluation. The clinical evaluation included a comprehensive medical history and physical examination. The medical history included information on symptoms during any prior episodes of Lyme disease, comorbidities, and current constitutional, musculoskeletal, and neurological symptoms. The physical examination was performed by an investigator blinded to disease status and included the American College of Rheumatology Glossary joint examination [11] and a standardized neurological examination of muscle strength, deep tendon reflexes, and sensation to light touch and vibration.
Serological studies. All subjects had blood drawn for serological testing. Serum samples were tested for IgM, IgG, and IgA antibodies to B. burgdorferi, by means of antibody-capture EIA [12] , and for the pattern of IgG reactivity to polypeptides of B. burgdorferi by means of Western blotting [13] . In addition, serum samples were tested for IgG antibodies to B. microti by indirect immunofluorescence [14] .
Confirmation of Lyme disease and babesiosis. We classified subjects as having Lyme disease on the basis of the CDC surveillance case definition, which requires (1) the presence of erythema migrans or (2) serological confirmation of infection along with evidence of у1 late manifestation of disease [15] . Late manifestations include arthritis, meningitis, cranial neuritis, radiculoneuropathy, encephalomyelitis, myocarditis, and acute second-or third-degree atrioventricular block.
Subjects were said to have acute concurrent infection if they reported a history of simultaneous Lyme disease and babesiosis, met the CDC criteria for Lyme disease, and had documented laboratory confirmation of acute babesial infection. Laboratory confirmation consisted of identification of intraerythrocytic parasites on a peripheral blood smear or an acute, 4-fold rise in titer of antibody to B. microti during the period of acute Lyme disease symptoms. Cases of coexposure were those in which patients met the CDC criteria for Lyme disease and had antibodies to B. microti but did not report an episode of acute concurrent infection. Confirmatory and supplementary information was sought from the ambulatory-care and hospital records for subjects who reported babesiosis.
Statistical analysis. All data were analyzed with the SAS statistical package on a SUN Sparcstation 2000 system (Sun Microsystems, Inc., Palo Alto, CA) [16] . Differences between groups were evaluated with the x 2 and Student's t-test for categorical and continuous outcomes, respectively. The Fisher's exact test was used to analyze categorical data in instances where у1 cells had expected counts !5. All P values were 2-tailed and were considered significant if !.05.
We estimated the population prevalence of babesiosis from our survey data and results of the clinical evaluation. Our sampling technique, which was designed to maximize case-finding, sampled 5 subjects who reported a history of Lyme disease and 2 subjects who reported no history of Lyme disease (1 of which had symptoms suggestive of possible infection), so we used weights to correct for this sampling. We assigned 1 of 3 weights to each observation (which reflected the relative frequency of these responses in the postal survey), according to group. These weighted values were then summed across the 3 survey groups to approximate the prevalence of exposure to Babesia species on Nantucket Island.
For example, there were 3 classes of subjects from the initial postal survey (3703 subjects): history of Lyme disease, no history of Lyme disease, and possibly infected with Lyme disease (see Methods, Participants). The proportions of subjects in the postal survey falling into each of these categories were as follows: history of Lyme disease (443 [12%]), no history of Lyme disease (1893 [51%]), and possibly infected with Lyme disease (1367 [37%]). The seroprevalence of Babesia among the examined subjects ( ) n p 336 was as follows: 16% for subjects with a history of Lyme disease in the initial postal survey (not necessarily CDC criteria-proven cases), 0% of subjects who gave no history of Lyme disease, and 11% of subjects who were identified as having a possible history of Lyme disease. To calculate the final population seroprevalence of Babesia exposure, the following equation was used:
(see Results).
Results
A total of 3703 of 6046 individuals responded to the postal questionnaire after a total of 3 mailings, for a response rate of 61%; 569 adults were invited for clinical evaluation, and 336 (57%) of them were evaluated for this analysis, of which 171 had prior Lyme disease. The seroprevalence of B. burgdorferi and B. microti in subjects' serum samples is detailed in table 1. The rate of Babesia seropositivity was higher among patients who had prior Lyme disease than among the controls (22% vs.
7%;
). P p .001 The estimated seroprevalence of babesiosis on Nantucket Island was 6.7% (95% CI, 4.0%, 9.4%). The prevalence of coexposure was 3.5% (95% CI, 1.5%, 5.4%). Thus, 26% of individuals seropositive for Lyme disease and 52% of individuals seropositive for babesiosis had serological evidence of coexposure when the data were adjusted with population weights (see Methods, Statistical Analysis).
Four patients (2%) reported acute concurrent infection with Lyme disease and babesiosis. All met CDC case criteria for Lyme disease and had positive smears for babesiosis or a 4- In table 3 , subjects who met the CDC criteria for Lyme disease are classified according to whether they had evidence of prior infection with babesiosis-either a positive titer of antibody to B. microti or a positive blood smear. Subjects who reported a history of babesiosis but lacked serological evidence or chart documentation were excluded from the analysis (5 patients). Evidence of previous babesial infection (found in 22% of subjects with Lyme disease) was not associated with increased severity of acute Lyme disease, as judged by the number of symptoms, hospitalization, or missed days of work. Anorexia was the only symptom associated by trend ( ) with pre-P p .05 vious exposure to Babesia. The prevalence of constitutional, musculoskeletal, or neurological symptoms and physical examination findings at the time of our evaluation (a mean of 6 years after the initial manifestations of Lyme disease) was also similar in both groups (table 4) .
Subjects with "atypical" presentations of Lyme disease, including systemic symptoms without an erythema migrans rash or a self-reported history of Lyme disease that did not meet CDC criteria, did not have a significantly different rate of seropositivity for B. microti (Lyme disease without erythema migrans vs. Lyme disease with erythema migrans: 20% vs. 22.1%, ; self-reported Lyme disease that did not meet CDC P p NS criteria vs. self-reported Lyme disease that did meet CDC criteria: 17.7% vs. 20.6%, ).
P p NS

Discussion
Most infections with B. microti appear to be subclinical. The majority of individuals in our study and in previous studies who had positive titers of antibody to Babesia reported no history of babesiosis [6, 8] . Although B. burgdorferi and B. microti are frequently acquired concomitantly, a concurrent diagnosis of both infections is uncommon. Human babesiosis is an opportunistic disease. Clinical babesiosis emerges with host risk factors such as increased age, prior splenectomy, immunosuppression, prematurity, and liver disease [17] [18] [19] .
Only 4 individuals in our study reported acute concurrent infection. All 4 had constitutional symptoms (i.e., high fevers) and findings of anemia or thrombocytopenia, which are most suggestive of babesiosis; these laboratory findings are uncharacteristic of Lyme disease alone [20] . The severity of their illnesses was moderate to severe, and 2 subjects required hospitalization. The conditions of all improved after antibiotic therapy against B. burgdorferi and B. microti; clindamycin and quinine were used against the latter, and either ceftriaxone or amoxicillin against the former. Host characteristics affect the likelihood of developing babesiosis but also may increase the likelihood of acute concurrent infection. Two of the 4 patients were in their seventies. None had undergone a splenectomy. In the present study, when coinfection occurred, the symptoms were most suggestive of babesiosis and the illness was quite severe, suggesting that coinfection with B. burgdorferi may alter symptomatic babesiosis.
The acute manifestations of concurrent infection have been described in 3 case reports and a recent report of a prospective study [17, [21] [22] [23] . One patient with concurrent Lyme disease and babesiosis had pancarditis and is the only reported fatality with Lyme disease [23] . Another reported patient had noncardiogenic pulmonary edema [17] . Krause et al. [21] described 26 subjects with concurrent infection and found them to have more symptoms and a greater duration of illness than those with Lyme disease alone. The long-term course of concurrent infection, however, has not been evaluated. Krause et al. [21] identified 26 residents of Block Island with symptoms and signs of acute concurrent infection from 1990 to 1994 and followed them until they became asymptomatic. Compared with patients infected with B. burgdorferi alone, the concurrently infected patients had more symptoms and a longer disease course; 13 of the 26 cases were symptomatic for у3 months. The authors suggest that impairment of host defenses by B. microti is one mechanism by which the severity of disease is increased.
Coexposure to babesiosis without acute concurrent infection may have prognostic significance. A number of reports document long-term morbidity in a subset of patients following acute Lyme disease [24] [25] [26] [27] . The mechanisms underlying these poor outcomes have yet to be elucidated, although several risk factors have been suggested, including delayed therapy and early dissemination. Coexposure has never been studied as a possible risk factor for long-term symptoms, although the implications for diagnosis and treatment are considerable. In contrast to patients with symptomatic concurrent infection, however, we found that individuals with Lyme disease and previous evidence of babesial infection did not have more severe acute illnesses. A mean of 6 years after the index illness, they did not have more symptoms or abnormal physical examination findings than individuals with Lyme disease alone.
We examined the hypothesis that "atypical" Lyme disease is due to undiagnosed babesial infection rather than Lyme disease. This is important because such presentations are common in areas of endemicity and because standard therapy for early Lyme disease, with amoxicillin or doxycycline, does not provide adequate coverage of B. microti. We found no evidence that patients who had Lyme disease without erythema migrans or who had self-reported Lyme disease not meeting the CDC case definition had a higher rate of reactivity to B. microti. Thus, "atypical" Lyme disease does not represent a significant number of undiagnosed cases of acute babesiosis.
Our population-based study also provides information on the extent of exposure to Babesia in a population where it is endemic. Previous studies on Nantucket Island have been based on case series or laboratory surveys and may have been subject to selection, ascertainment, or referral bias. Ruebush et al. [6] found that 11 (2%) of 577 serum samples collected at Nantucket Cottage Hospital reacted to B. microti. Our findings suggest that the seroprevalence is higher, at 6%.
Only 4 (8%) of 48 seropositive subjects reported a history of babesiosis. An additional 13 subjects gave a history of babesiosis but did not have sera reactive to B. microti. Six of these 13 subjects had prior positive serology confirmed by medical record review, 3 as recently as 3 years before our assay. The likely explanation is that titers of antibody to Babesia decay over time. Five of 11 patients whose medical records were available for review had clinical illness within 2 years of this followup study. B. burgdorferi titers tend to remain positive for a longer period of time (i.e., 5-10 years), particularly if treatment against the organism is administered at a disseminated stage [9, 24] . This serological decay of titers of antibody to Babesia would suggest that the seroprevalence understates the true percentage of residents of Nantucket Island and Block Island ever exposed to B. microti. We conclude that exposure to B. microti is common and usually asymptomatic.
In the present study, 22% of individuals with prior Lyme disease in Nantucket had evidence of prior babesial infection. This figure exceeds estimates from studies in other areas of endemicity, a finding suggesting that B. microti may be more prevalent on Nantucket Island. Krause et al. [4] conducted a serological survey in Connecticut and found that 9.5% of subjects seropositive for B. burgdorferi also had antibodies to B. microti. In a study on Block Island, 11% of patients with acute Lyme disease had serological or parasitological evidence of con-comitant babesial infection [21] . On the basis of these studies, it appears that the prevalence of B. microti is higher on Nantucket Island than in other areas where it is endemic. This study had several potential limitations that require comment. Because it was retrospective, some misclassification of disease status may have occurred. This was mitigated by standardized serological testing, adherence to CDC case criteria for Lyme disease, and acceptance of only indirect immunofluorescence reactivity to B. microti as presumptive evidence of babesial infection. This assay for Babesia is sensitive and highly specific [14] . Ideally, confirmation would require identification of intraerythrocytic organisms on a peripheral blood smear during the acute illness. However, none of our subjects was studied in the acute phase of illness; thus, the likelihood of detecting parasitemia would be very low.
For subjects with a history of acute babesiosis, confirmatory laboratory data were used from ambulatory care and hospital records. Only patients with laboratory confirmation were accepted as having had babesial infection.
Because titers of antibody to B. microti can decay over time, some patients classified as having Lyme disease alone may have had both diseases. This would likely raise the prevalence estimate for babesiosis and (if titers of antibody to Babesia declined faster than those to B. burgdorferi) might lead to a conservative bias in a comparison of outcomes of cases of Lyme disease alone versus those in cases of coexposure. When we repeated the analyses, restricting the sample to patients within 3 years of the initial illness in an attempt to minimize the amount of deterioration in titers of antibody to Babesia, we found no differences in the conclusions.
Finally, because most cases of babesiosis are subclinical, the possibility that some individuals may have actually contracted the 2 infections at different times cannot be excluded. Previous serological studies, however, suggest that simultaneous transmission is common in areas of endemicity [28] .
Though participation rates for the survey and for the clinical evaluation were high, selection bias may have occurred. We studied a sample of nonrespondents and found that they did not differ from respondents with regard to history of Lyme disease or Lyme-related symptoms [9] , thus confirming the validity of our sample.
Exposure to B. microti is common in patients with Lyme disease, usually with no history of clinical babesiosis. Coexposure to Babesia probably does not predispose to more severe or persistent symptoms following acquisition of Lyme disease. Though antibiotic therapy for Lyme disease does not cover B. microti, outcomes for patients with evidence of dual infection are not poorer than for patients with Lyme disease alone. However, in practice, because some patients concurrently infected with Lyme disease and babesiosis have fulminant courses, patients who have Lyme disease with severe or atypical symptoms should be investigated for concurrent babesiosis and treated accordingly. High fever, anemia, and thrombocytopenia are not common in Lyme disease and should raise clinical suspicion of concurrent infection with B. microti [17, 20, 22, 23] .
Studies are needed to determine if there are additional risk factors for poor long-term outcomes after concurrent infection and to develop a more precise clinical prediction rule for concurrent Lyme disease and babesiosis. Further studies are also needed to assess the frequency and significance of concurrent infection with other organisms, such as the agent causing human granulocytic ehrlichiosis [29] .
